Fulcrum Capital LLC Acquires 313 Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI)

Fulcrum Capital LLC lifted its stake in SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report) by 0.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 46,098 shares of the exchange traded fund’s stock after buying an additional 313 shares during the period. Fulcrum Capital LLC owned about 0.06% of SPDR S&P Biotech ETF worth $4,116,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Roundview Capital LLC increased its stake in SPDR S&P Biotech ETF by 275.4% in the first quarter. Roundview Capital LLC now owns 7,599 shares of the exchange traded fund’s stock valued at $683,000 after acquiring an additional 5,575 shares during the period. U.S. Capital Wealth Advisors LLC bought a new position in shares of SPDR S&P Biotech ETF in the first quarter worth about $222,000. Synovus Financial Corp raised its stake in shares of SPDR S&P Biotech ETF by 559.1% in the first quarter. Synovus Financial Corp now owns 15,462 shares of the exchange traded fund’s stock worth $1,390,000 after acquiring an additional 13,116 shares during the last quarter. Vontobel Holding Ltd. boosted its stake in shares of SPDR S&P Biotech ETF by 6.7% in the 1st quarter. Vontobel Holding Ltd. now owns 6,400 shares of the exchange traded fund’s stock valued at $575,000 after purchasing an additional 400 shares during the last quarter. Finally, Sequoia Financial Advisors LLC boosted its stake in shares of SPDR S&P Biotech ETF by 17.6% in the 1st quarter. Sequoia Financial Advisors LLC now owns 2,234 shares of the exchange traded fund’s stock valued at $201,000 after purchasing an additional 334 shares during the last quarter.

SPDR S&P Biotech ETF Trading Up 0.4 %

Shares of NYSEARCA XBI opened at $95.13 on Monday. The firm has a market capitalization of $7.30 billion, a PE ratio of 11.47 and a beta of 0.97. SPDR S&P Biotech ETF has a 1 year low of $63.80 and a 1 year high of $103.52. The firm’s 50-day moving average is $92.81 and its 200-day moving average is $81.79.

SPDR S&P Biotech ETF Company Profile

(Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Articles

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.